Chemomab Therapeutics Ltd.: Form 10-K for the period ended Dec 31, 2022
Filed with the SEC on Mar 20, 2023 and accepted by EDGAR at Mar 20, 2023, 06:10 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2022-01-01 to 2022-12-31 | $17.0m | us-gaap:ResearchAndDevelopmentExpense |
| Income tax | 12 months2022-01-01 to 2022-12-31 | −$534.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2022-01-01 to 2022-12-31 | −$27.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2022-01-01 to 2022-12-31 | $0.12 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2022-01-01 to 2022-12-31 | $0.12 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2022-01-01 to 2022-12-31 | 227,589,288 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2022-01-01 to 2022-12-31 | −$20.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2022-01-01 to 2022-12-31 | $68.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-12-31 | $13.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-12-31 | $41.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-12-31 | $43.1m | us-gaap:Assets |
| Current liabilities | At period end2022-12-31 | $6.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-12-31 | $6.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-12-31 | $36.2m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2022-12-31 | 220,996,240 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001178913-23-001041. Last ingested by Listed: Oct 30, 2026, 16:42 ET. Listed shows no prices and gives no investment advice.